Tag - PDL

Provider Alert!
22Mar

Provider Alert! Change in PDL Status for Antivirals, Oral Drug Class

Date: March 22, 2024 Attention: All Providers Effective date: March 7, 2024 Call to action: Texas Children’s Health Plan (TCHP) would like to let providers know that effective March 7, 2024, valganciclovir tablet will now be preferred along with brand Valcyte. This is in response to the shortage of the brand product Valcyte by the manufacturer. How this impacts providers: The change will allow providers to prescribe the generic without requiring preferred drug list (PDL) prior authorization at this time and continue accessing necessary...

By Facilities, HHSC, OB/GYNs, Office Managers, Pharmacy, Primary Care Providers, Provider Alert, Specialists, 0 CommentsRead more...
Provider Alert!
16Feb

Provider Alert! Generic for Rapumune Tablets and Solutions (Sirolimus) Now Preferred

Date: February 16, 2024 Attention: All Providers Effective: February 12, 2024 Call to action: Texas Children’s Health Plan (TCHP) would like to let providers know that effective February 12, 2024, sirolimus tablets and generics will now be preferred. This is in response to the discontinuation of the brand product Rapamune by the manufacturer. How this impacts providers: The change will allow providers to prescribe the generic without requiring Preferred Drug List (PDL) prior authorization at this time and continue accessing necessary medication for their...

By OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , 0 CommentsRead more...
Provider Alert!
19Jan

Provider Alert! Updated: Medicaid Preferred Drug List and Formulary Changes

Date: January 18, 2024 Attention: All Providers Effective Date: January 26, 2024 This is an update for a communication that was previously posted on 12/18/2023. Call to action: Texas Children’s Health Plan (TCHP) would like to let providers know that effective January  26, 2024, select medication(s) moved from “preferred” or “non-reviewed” to “non-preferred” status. A summary of the changes is included below. Resource: https://www.txvendordrug.com/formulary/preferred-drugs Changes with biggest impact to Texas Children Health Plan members and providers: The drugs listed below were either not previously reviewed (NR)...

By OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , 0 CommentsRead more...
Provider Alert!
02Jan

Provider Alert! Change in Preferred Drug List Status for Otic, Antibiotics Drug Class

Date: December 28, 2023 Attention: All Providers Effective Date: December 18, 2023 Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective December 18, 2023, the Texas Health and Human Services Commission (HHSC) removed non-preferred status from generic ciprofloxacin/dexamethasone otic solution on the preferred drug list. This is in response to the discontinuation of the product by the manufacturer. The preferred status of the brand name Ciprodex will not change to allow any remaining stock to be used. How this...

By OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , 0 CommentsRead more...
Provider Alert!
18Dec

Provider Alert! Medicaid Preferred Drug List and Formulary Changes

Date: December 18, 2023 Attention: Providers Effective Date: January 25, 2024 Call to action: Texas Children’s Health Plan (TCHP) would like to notify providers that effective January 26, 2024, select medication(s) moved from “preferred” or “non-reviewed” to “non-preferred” status. A summary of the changes is included below. Resource: https://www.txvendordrug.com/formulary/preferred-drugs Changes with biggest impact to Texas Children Health Plan members and providers: The drugs listed below were either not previously reviewed (NR) and became non-preferred (NPD) or previously considered a preferred agent (PDL) but now have...

By OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , , 0 CommentsRead more...
Provider Alert!
08Dec

Provider Alert! Change in Preferred Drug List Status for Glucocorticoids, Inhaled Drug Class

Date: December 8, 2023 Attention: Providers Effective date: December 15, 2023 Call to action: Effective December 15, 2023, the Texas Health and Human Services (HHS) removed non-preferred status from generic fluticasone hydrofluoroalkane (HFA) and brand Qvar products on the preferred drug list. This is in response to the discontinuation of the product by the manufacturer. The preferred status of the brand name Flovent HFA and Flovent Diskus will not change to allow for any remaining stock to be used. How this impacts providers: The change...

By OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, 0 CommentsRead more...
Provider Alert!
08Nov

Provider Alert! Updates to the Preferred Drug List (PDL) for Androgenic agents, Macrolides-Ketolides, Antiviral, Bronchodilator and Growth Hormone drug classes

Date: November 8, 2023 Attention: All Providers Effective Date: October 31, 2023 Call to action: Texas Health and Human Services (HHSC) moved select medication(s) listed below to “preferred” status due to various drug shortages at this time. We are notifying providers more options to prescribe your members if they cannot obtain their current medication(s).  A summary of the changes is included below. Impacted medications(s) Preferred medication Type of change Effective Date Androgel [B] Testosterone Gel (TOPICAL) [G] Generic now preferred October 16, 2023 Valcyte [B] Valganciclovir solution (ORAL) [G] Generic now preferred October 16, 2023 Nordotropin [B] Omnitrope*...

By OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , , , 0 CommentsRead more...
Provider Alert!
03Nov

Provider Alert! Change in Preferred Drug List Status for the Bronchodilators, Beta Agonist

Date: November 3, 2023 Attention: All Providers Effective Date: October 31, 2023 Call to action: Texas Children’s Health Plan (TCHP) would like to let providers know that effective October 31, 2023, the Texas Health and Human Services Commission (HHSC) removed non-preferred status from generic levalbuterol inhalation solution on the preferred drug list. This is in response to the manufacturer shut down, therefore the discontinuation of the product. The preferred status of the brand name Xopenex inhalation solution (NDCs: 17478-0172-24, 17478-0173-24, 17478-0174-24) will not change...

By OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , , 0 CommentsRead more...
Provider Alert!
21Jul

Provider Alert! Medicaid Preferred Drug List and Formulary Changes

Date: July 21, 2023 Attention: All Providers Effective Date: July 27, 2023 Call to action: Texas Children’s Health Plan (TCHP) would like to let providers know that effective July 27, 2023, select medication(s) moved from “preferred” to “non-preferred” status. A summary of the changes is included below. Resource: https://www.txvendordrug.com/formulary/preferred-drugs Changes with biggest impact to Texas Children Health Plan members and providers: The drugs listed below were either not previously reviewed (NR) and became non-preferred (NPD) or previously considered a preferred agent (PDL) but now have changed...

By Facilities, OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , , 0 CommentsRead more...
Provider Alert!
25Apr

Provider Alert! Lidocaine 5% Patch Added To PDL

Date: April 21, 2023 Attention: All Providers Effective Date: April 3, 2023 Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective April 3, 2023, the Texas Health and Human Services Commission (HHSC) temporarily removed the non-preferred status from the generic product, Lidocaine 5% patches on the preferred drug list (PDL). The preferred status of the brand name products (NDC 63481-0687-06) will not change to allow for any existing stock available to be utilized. This is in response...

By Facilities, OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , , 0 CommentsRead more...